University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Democritus University of Thrace, Alexandroupolis, Greece.
Int J Low Extrem Wounds. 2020 Sep;19(3):236-241. doi: 10.1177/1534734620921677. Epub 2020 Jun 5.
New antimicrobial agents have been developed to treat infections caused by methicillin-resistant and other multidrug-resistant pathogens. Dalbavancin is a novel semisynthetic lipoglycopeptide antibiotic, particularly active against methicillin-resistant . Due to its unique pharmacological characteristics and longer half-life, it can be administered once-weekly or every 15 days and in outpatient setting. Currently, it is indicated for complicated skin and soft tissue infections, but accumulating evidence points to its off-label efficacy in osteomyelitis and endocarditis. Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment.
新的抗菌药物已经被开发出来，用于治疗耐甲氧西林和其他多药耐药病原体引起的感染。达巴万星是一种新型半合成糖肽类抗生素，对耐甲氧西林金黄色葡萄球菌具有特别的活性。由于其独特的药理学特性和较长的半衰期，它可以每周或每 15 天给药一次，并可在门诊环境下使用。目前，它被批准用于治疗复杂的皮肤和软组织感染，但越来越多的证据表明它在骨髓炎和心内膜炎中的疗效超出了标签说明。需要进一步的经验来增加我们对达巴万星在更广泛的需要长期抗菌治疗的革兰氏阳性感染中的作用的了解。
